{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:05:44Z","timestamp":1787061944108,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00774-022-01393-9","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T05:12:19Z","timestamp":1670908339000},"page":"203-211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of denosumab on bisphosphonate-treated osteoporosis and osteopenia in systemic rheumatic disease patients receiving glucocorticoids"],"prefix":"10.1007","volume":"41","author":[{"given":"Shin-ya","family":"Tamechika","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichiro","family":"Ohmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0489-2611","authenticated-orcid":false,"given":"Taio","family":"Naniwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"key":"1393_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/BF02938618","volume":"5","author":"JR Curtis","year":"2007","unstructured":"Curtis JR, Saag KG (2007) Prevention and treatment of glucocorticoid-induced osteoporosis. Curr Osteoporos Rep 5:14\u201321. https:\/\/doi.org\/10.1007\/BF02938618","journal-title":"Curr Osteoporos Rep"},{"key":"1393_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00223-006-0019-1","volume":"79","author":"TP Van Staa","year":"2006","unstructured":"Van Staa TP (2006) The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 79:129\u2013137. https:\/\/doi.org\/10.1007\/s00223-006-0019-1","journal-title":"Calcif Tissue Int"},{"key":"1393_CR3","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1002\/art.22975","volume":"56","author":"WF Lems","year":"2007","unstructured":"Lems WF (2007) Bisphosphonates and glucocorticoids: effects on bone quality. Arthritis Rheum 56:3518\u20133522. https:\/\/doi.org\/10.1002\/art.22975","journal-title":"Arthritis Rheum"},{"key":"1393_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/s0889-8529(02)00064-6","volume":"32","author":"KG Saag","year":"2003","unstructured":"Saag KG (2003) Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am 32:135\u2013157. https:\/\/doi.org\/10.1016\/s0889-8529(02)00064-6","journal-title":"Endocrinol Metab Clin North Am"},{"key":"1393_CR5","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","volume":"15","author":"TP Van Staa","year":"2000","unstructured":"Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993\u20131000. https:\/\/doi.org\/10.1359\/jbmr.2000.15.6.993","journal-title":"J Bone Miner Res"},{"key":"1393_CR6","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1046\/j.1365-2796.2003.01219.x","volume":"254","author":"P Vestergaard","year":"2003","unstructured":"Vestergaard P, Olsen ML, Paaske Johnsen S, Rejnmark L, S\u00f8rensen HT, Mosekilde L (2003) Corticosteroid use and risk of hip fracture: a population-based case-control study in Denmark. J Intern Med 254:486\u2013493. https:\/\/doi.org\/10.1046\/j.1365-2796.2003.01219.x","journal-title":"J Intern Med"},{"key":"1393_CR7","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/art.21984","volume":"55","author":"JR Curtis","year":"2006","unstructured":"Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, Kovac SH, Spettell CM, Saag KG (2006) Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 55:420\u2013426. https:\/\/doi.org\/10.1002\/art.21984","journal-title":"Arthritis Rheum"},{"key":"1393_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.bone.2006.02.005","volume":"39","author":"A Angeli","year":"2006","unstructured":"Angeli A, Guglielmi G, Dovio A, Capelli G, de Feo D, Giannini S, Giorgino R, Moro L, Giustina A (2006) High prevalence of asymptomatic vertebral fractures in postmenopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39:253\u2013259. https:\/\/doi.org\/10.1016\/j.bone.2006.02.005","journal-title":"Bone"},{"key":"1393_CR9","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/acr.23279","volume":"69","author":"L Buckley","year":"2017","unstructured":"Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J et al (2017) American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 69:1095\u20131110. https:\/\/doi.org\/10.1002\/acr.23279","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1393_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00774-014-0586-6","volume":"32","author":"Y Suzuki","year":"2014","unstructured":"Suzuki Y, Nawata H, Soen S, Fujiwara S, Nakayama H, Tanaka I, Ozono K, Sagawa A, Takayanagi R, Tanaka H, Miki T, Masunari N, Tanaka Y (2014) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab 32:337\u2013350. https:\/\/doi.org\/10.1007\/s00774-014-0586-6","journal-title":"J Bone Miner Metab"},{"key":"1393_CR11","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1007\/s00198-012-1958-1","volume":"23","author":"S Lekamwasam","year":"2012","unstructured":"Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S et al (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23:2257\u20132276. https:\/\/doi.org\/10.1007\/s00198-012-1958-1","journal-title":"Osteoporos Int"},{"key":"1393_CR12","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2213-8587(18)30075-5","volume":"6","author":"KG Saag","year":"2018","unstructured":"Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, Chapurlat R, Wang A, Pannacciulli N, Lems WF (2018) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, activecontrolled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 6:445\u2013454. https:\/\/doi.org\/10.1016\/S2213-8587(18)30075-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1393_CR13","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/art.40874","volume":"71","author":"KG Saag","year":"2019","unstructured":"Saag KG, Pannacciulli N, Geusens P, Adachi JD, Messina OD, Morales-Torres J, Emkey R, Butler PW, Yin X, Lems WF (2019) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four\u2013month randomized, double-blind, double-dummy trial. Arthritis Rheumatol 71:1174\u20131184. https:\/\/doi.org\/10.1002\/art.40874","journal-title":"Arthritis Rheumatol"},{"key":"1393_CR14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2015.03.002","volume":"75","author":"CC Mok","year":"2015","unstructured":"Mok CC, Ho LY, Ma KM (2015) Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial. Bone 75:222\u2013228. https:\/\/doi.org\/10.1016\/j.bone.2015.03.002","journal-title":"Bone"},{"key":"1393_CR15","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/14397595.2017.1416919","volume":"28","author":"T Suzuki","year":"2018","unstructured":"Suzuki T, Nakamura Y, Kato H (2018) Significant improvement of bone mineral density by denosumab without bisphosphonate pre-treatment in glucocorticoid-induced osteoporosis. Mod Rheumatol 28:885\u2013889. https:\/\/doi.org\/10.1080\/14397595.2017.1416919","journal-title":"Mod Rheumatol"},{"key":"1393_CR16","doi-asserted-by":"publisher","first-page":"100293","DOI":"10.1016\/j.bonr.2020.100293","volume":"13","author":"Y Hirooka","year":"2020","unstructured":"Hirooka Y, Nozaki Y, Inoue A, Li J, Shiga T, Kishimoto K, Sugiyama M, Kinoshita K, Funauchi M, Matsumura I (2020) Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment. Bone Rep 13:100293. https:\/\/doi.org\/10.1016\/j.bonr.2020.100293","journal-title":"Bone Rep"},{"key":"1393_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11657-018-0451-7","volume":"13","author":"SY Tamechika","year":"2018","unstructured":"Tamechika SY, Sasaki K, Hayami Y, Ohmura SI, Maeda S, Iwagaitsu S, Naniwa T (2018) Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial. Arch Osteoporos 13:67. https:\/\/doi.org\/10.1007\/s11657-018-0451-7","journal-title":"Arch Osteoporos"},{"key":"1393_CR18","first-page":"817","volume":"105","author":"K Furuta","year":"2008","unstructured":"Furuta K, Adachi K, Arima N, Tanaka S, Miki M, Azumi T, Koshino K, Kinoshita Y (2008) Study on the recognition of Japanese adults for upper abdominal symptoms (in Japanese). Nippon Shokakibyo Gakkai Zasshi 105:817\u2013824","journal-title":"Nippon Shokakibyo Gakkai Zasshi"},{"key":"1393_CR19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1359\/jbmr.090716","volume":"25","author":"DL Kendler","year":"2010","unstructured":"Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25:72\u201381. https:\/\/doi.org\/10.1359\/jbmr.090716","journal-title":"J Bone Miner Res"},{"key":"1393_CR20","volume-title":"R: A language and environment for statistical computing","author":"R Core Team. R","year":"2013","unstructured":"R Core Team. R (2013) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna"},{"key":"1393_CR21","unstructured":"National Cancer Institute (2020) Common terminology criteria for adverse events, version 5.0. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf 2017"},{"key":"1393_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40268-016-0146-8","volume":"16","author":"H Matsuno","year":"2016","unstructured":"Matsuno H (2016) Assessment of distal radius bone mineral density in osteoporosis patients receiving denosumab, including those with rheumatoid arthritis and those receiving oral glucocorticoids. Drugs R D 16:347\u2013353. https:\/\/doi.org\/10.1007\/s40268-016-0146-8","journal-title":"Drugs R D"},{"key":"1393_CR23","doi-asserted-by":"publisher","first-page":"e0193846","DOI":"10.1371\/journal.pone.0193846","volume":"13","author":"K Iseri","year":"2018","unstructured":"Iseri K, Iyoda M, Watanabe M, Matsumoto K, Sanada D, Inoue T, Tachibana S, Shibata T (2018) The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial. PLoS ONE 13:e0193846. https:\/\/doi.org\/10.1371\/journal.pone.0193846","journal-title":"PLoS ONE"},{"key":"1393_CR24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.bone.2011.07.011","volume":"49","author":"T Matsumoto","year":"2011","unstructured":"Matsumoto T, Ito M, Hayashi Y, Hirota T, Tanigawara Y, Sone T, Fukunaga M, Shiraki M, Nakamura T (2011) A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures\u2013a randomized, active comparator, double-blind study. Bone 49:605\u2013612. https:\/\/doi.org\/10.1016\/j.bone.2011.07.011","journal-title":"Bone"},{"key":"1393_CR25","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s00774-020-01091-4","volume":"38","author":"T Matsumoto","year":"2020","unstructured":"Matsumoto T, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Nakano T, Ito M, Tomomitsu T, Hirakawa A, Soen S (2020) Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA). J Bone Miner Metab 38:522\u2013532. https:\/\/doi.org\/10.1007\/s00774-020-01091-4","journal-title":"J Bone Miner Metab"},{"key":"1393_CR26","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00774-016-0792-5","volume":"35","author":"K Ebina","year":"2017","unstructured":"Ebina K, Kashii M, Hirao M, Hashimoto J, Noguchi T, Koizumi K, Kitaguchi K, Matsuoka H, Iwahashi T, Tsukamoto Y, Yoshikawa H (2017) Comparison of the effects of denosumab between a native vitamin D combination and an active vitamin D combination in patients with postmenopausal osteoporosis. J Bone Miner Metab 35:571\u2013580. https:\/\/doi.org\/10.1007\/s00774-016-0792-5","journal-title":"J Bone Miner Metab"},{"key":"1393_CR27","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00198-021-06174-0","volume":"33","author":"F Cosman","year":"2022","unstructured":"Cosman F, Kendler DL, Langdahl BL, Leder BZ, Lewiecki EM, Miyauchi A, Rojeski M, McDermott M, Oates MK, Milmont CE, Libanati C, Ferrari S (2022) Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporos Int 33:1243\u20131256. https:\/\/doi.org\/10.1007\/s00198-021-06174-0","journal-title":"Osteoporos Int"},{"key":"1393_CR28","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1177\/1060028018768808","volume":"52","author":"P Morizio","year":"2018","unstructured":"Morizio P, Burkhart JI, Ozawa S (2018) Denosumab: a unique perspective on adherence and cost-effectiveness compared with oral bisphosphonates in osteoporosis patients. Ann Pharmacother 52:1031\u20131041. https:\/\/doi.org\/10.1177\/1060028018768808","journal-title":"Ann Pharmacother"},{"key":"1393_CR29","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s00198-020-05507-9","volume":"31","author":"G Koller","year":"2020","unstructured":"Koller G, Goetz V, Vandermeer B, Homik J, McAlister FA, Kendler D, Ye C (2020) Persistence and adherence to parenteral osteoporosis therapies: a systematic review. Osteoporos Int 31:2093\u20132102. https:\/\/doi.org\/10.1007\/s00198-020-05507-9","journal-title":"Osteoporos Int"},{"key":"1393_CR30","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR, FLEX Research Group (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927\u20132938. https:\/\/doi.org\/10.1001\/jama.296.24.2927","journal-title":"JAMA"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-022-01393-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-022-01393-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-022-01393-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T22:15:44Z","timestamp":1679868944000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-022-01393-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1393"],"URL":"https:\/\/doi.org\/10.1007\/s00774-022-01393-9","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,13]]},"assertion":[{"value":"3 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T.N. received grants from Chugai Pharmaceutical Co., Ltd, speaker fees from Chugai Pharmaceutical Co., Ltd, Ono Pharmaceutical Co., Ltd, Eisai Co., Ltd, and Astellas Pharma Inc. S.T. received speaker fees from Chugai Pharmaceutical Co., Ltd, Ono Pharmaceutical Co., Ltd, Eisai Co., Ltd, Daiichi-Sankyo Co., Ltd., and Astellas Pharma Inc. S.O. received speaker fees from Chugai Pharmaceutical Co., Ltd, Ono Pharmaceutical Co., Ltd, Daiichi-Sankyo Co., Ltd., and Astellas Pharma Inc. S.M. received speaker fees from Ono Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}